Colchicine therapy in children with FMF by A-M Knieper et al.
ORAL PRESENTATION Open Access
Colchicine therapy in children with FMF
A-M Knieper1*, J Klotsche2, D Föll3, H Wittkowski3, E Lainka4, T Kallinich1
From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015
Introduction
Colchicine treatment is the standard therapy for prophy-
laxis of attacks and amyloid deposition in familial Mediter-
ranean fever. In the guidelines of 2007 an initial dosage in
regard of the age of the patient is recommended (0.5 mg/
day for children <5 years of age, 1.0 mg/day for children
5-10 years of age, 1.5 mg/day for children >10 years of age).
Objectives
The following objective were raised in the study: To
analyze factors, which influences the individual colchi-
cine dose in children with FMF. To analyze the impact
of dose adjustment on the clinical course and the degree
of subclinical inflammation. To analyze parameters,
which predict dose increase in the upcoming 12 month
including levels of SAA and S100A12-molecules
Patients and methods
Data of the FMF-patients were extracted from the AID-
Net-register and analysed with SPSS (Patient number
n=409, Visit number n= 4750). Correlation and regression
analyses were performed with the aim of an multivariant
analyses. The extraction of the data was in January 2015.
Results
Colchicine dose correlates with the genotype. It further
increases linearly with an increase of age (1 - 18 years),
body weight and body surface area. The correlation of
colchicine dose with body surface revealed an average of
1 mg colchicine / 1 m2.
A high response rate in the CRP and the attack rate is
shown both at time of therapy introduction (70% response
CRP: 45.5% / attack frequency: 61.4%), as well as dose
increases during the course of the disease (with an
increase of 1.0 mg to 1 5 mg: 70% Response CRP: 32.1% /
attack frequency: 42.3%).
The severity of disease at diagnosis increases the likeli-
hood of a dose raise in the first 12 months and 24 months
after therapy introduction.
An increase of classical inflammatory markers (CRP,
SAA) and S100 proteins show a significant correlation to a
dose increase in the following 12 or 24 months (p <0.05).
Conclusion
The mutation, the age, the body weight, the body surface
area and the initial disease severity affect the colchicine
dose.
Dose increase is effective to control disease activity and
subclinical inflammation. This effect was also observed
when increasing the dose from 1.5 mg to 2.0 mg a day.
An increase in the classical inflammation markers and
S100A12- or S100A8 / A9-value are predictors for an
upcoming increase in the dose in the next 12 or 24 months,
None of these factors showed an advantage in predicting a
higher dose.
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